High brightness, highly directional organic light-emitting diodes as light sources for future light-amplifying prosthetics in the optogenetic management of vision loss

Optogenetic control of retinal cells transduced with light-sensitive channelrhodopsins can enable restoration of visual perception in patients with vision loss. However, a light intensity orders of magnitude higher than ambient light conditions is required to achieve robust cell activation. Relatively bulky wearable light amplifiers are currently used to deliver sufficient photon flux (>10¹⁶ photons/cm²/s in a ±10° emission cone) at a suitable wavelength (e.g., 600 nm for channelrhodopsin ChrimsonR). Here, ultrahigh brightness organic light-emitting diodes (OLEDs) with highly directional emission are developed, with the ultimate aim of providing high-resolution optogenetic control of thousands of retinal cells in parallel from a compact device. The orange-emitting phosphorescent OLEDs use doped charge transport layers, generate narrowband emission peaking at 600 nm, and achieve a luminance of 684 000 cd m^–2 at 15 V forward bias. In addition, tandem-stack OLEDs with a luminance of 1 152 000 cd m^–2 and doubled quantum efficiency are demonstrated, which greatly reduces electrical and thermal stress in these devices. At the photon flux required to trigger robust neuron firing in genetically modified retinal cells and when using heat sinking and realistic duty cycles (20% at 12.5 Hz), the tandem-stack OLEDs therefore show a greatly improved half-brightness lifetime of 800 h.